Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 PRESIDENTS REPORT TO SHAREHOLDERS - Zivo Bioscience, Inc. | f8k011413_ex99z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 14, 2013
HEALTH ENHANCEMENT PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Nevada |
| 000-30415 |
| 87-0699977 |
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of incorporation) |
| File Number) |
| Identification No.) |
7 West Square Lake Rd., Bloomfield Hills, Michigan 48302
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (248) 452-9866
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On January 14, 2013, the Company released the President’s Report To Shareholders dated January 14, 2013, a copy of which is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 – President’s Report to Shareholders dated January 14, 2013
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH ENHANCEMENT PRODUCTS, INC.
Date: January 14, 2013 | By: /s/ PHILIP M, RICE II |
| Philip M. Rice, II, Chief Financial Officer |
2